Mepivacaine
Indications
Mepivacaine is used for:
Infiltration Anesthesia
Adult Dose
Infiltration Anesthesia
Up to 400 mg (80 mL of 0.5% or 40 mL of 1% solution)
Cervical/Brachial/Intercostal or Pudendal Block
50-400 mg (5-40 mL) of 1% or 100-400 mg (5-20 mL) 2% solution; for pudental block inject one half total dose each side; not to exceed 400 mg
Transvaginal Block
Up to 300 mg (30 mL of 1% solution); inject one half total dose each side; not to exceed 300 mg
Paracervical Block
Up to 200 mg (20 mL of 1% solution); inject one half total dose each side; not to exceed 200 mg
Child Dose
Renal Dose
Administration
Usually no more than 400 mg/dose; doses up to 550 mg has been used but rare & given no more frequently than q1.5hr; no more than 1000 mg in 24 hours
Use preservative-free preparations for spinal or epidural anesthesia
Contra Indications
Hypersensitivity to mepivacaine or amide anesthetics, sensitivity to parabens
Precautions
Some formulations may contain sulfites
History of malignant hyperthermia
Monitor patient's state of consciousness following the injection; anxiety, dizziness, restlessness, tremors, depression, or blurred vision may be signs of CNS toxicity
DO NOT use solutions with epinephrine in distal areas of body (eg, digit, nose, ear)
Respiratory arrest reported with use
Unintentional intravascular injection may result in seizures
Addition of vasoconstrictor, epinephrine, will promote local hemostasis, decrease systemic absorption, and increase duration of action
Risk of chondrolysis if receiving continuous intra-articular infusion following arthroscopic or other surgical procedures
Methemoglobinemia
Use of local anesthetics may cause methemoglobinemia, a serious condition that must be treated promptly; patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition
Advise patients or caregivers to seek immediate medical attention if patient experiences the following signs or symptoms: pale, gray, or blue colored skin (cyanosis); headache; rapid heart rate; shortness of breath; lightheadedness; or fatigue; discontinue drug and any other oxidizing agents; depending on severity of signs and symptoms, patients may respond to supportive care, including oxygen therapy and hydration; a more severe clinical presentation may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen
Pregnancy-Lactation
Pregnancy Category: C
Lactation: Not known if excreted in breast milk
Interactions
Side Effects
Side effects of Mepivacaine :
Frequency Not Defined
Systemic dose-related toxicity
Underventilation/apnea ("Total or High Spinal"),
Hypotension
Acidosis
Systemic diseases which alter protein production/competition of other drugs for protein binding sites
Angioneurotic edema (including laryngeal edema), syncope, depression of the myocardium, decreased cardiac output, heart block, hypotension (or sometimes hypertension), bradycardia, ventricular arrhythmias, and possibly cardiac arrest
Excitation and/or depression, restlessness, anxiety, dizziness, tinnitus, blurred vision, tremors (possible convulsions), chills, constriction of the pupils, elevated temperature, paralysis of the of consciousness, persistent anesthesia, paresthesia, weakness, paralysis of the lower extremities/sphincter control, headache, septic meningitis, meningismus, cranial nerve palsies due to traction on nerves from of cerebrospinal fluid
Urticaria, pruritus, erythema, excessive sweating
Nausea, vomiting
Backache
Urinary retention, fecal/urinary incontinence
Sneezing, respiratory paralysis (secondary to spinal block)
Loss of perineal sensation and sexual function
Anaphylactoid-like symptomatology (including severe hypotension)
Slowing of labor; increased incidence of forceps delivery
Mode of Action
Local anesthetics prevent generation/conduction of nerve impulses by reducing sodium permeability and increasing action potential threshold